13F Holdings
中文EN

KYTX Kyverna Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1994702 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.0%
TTM EPS YoY26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-110.7%
ROA-83.8%
ROIC (approx.)-105.6%
Asset turnover—

Leverage & solvency

Liabilities / assets29.7%
Debt / equity0.19x
Current ratio7.01x
Interest coverage-64.90x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$133.72M$112.47M$49.92M
SG&A expense$36.11M$30.13M$12.48M
Operating income-$169.83M-$142.60M-$62.41M
Interest expense$489,000$142,000$187,000
Income tax$0$0$0
Net income-$161.31M-$127.48M-$60.37M
EBITDA-$168.03M-$140.47M-$60.70M
EPS (basic)-3.64-3.33-89.61
EPS (diluted)-3.64-3.33-89.61
Weighted avg. shares (diluted)44.26M38.33M673,622
Balance sheet
Cash & equivalents$124.09M$96.62M$34.65M
Short-term investments$155.16M$189.36M$22.90M
Current assets$282.95M$290.60M$60.66M
PP&E, net$1.55M$3.35M$2.33M
Total assets$293.83M$304.64M$75.19M
Current liabilities$36.49M$33.76M$19.86M
Long-term debt$24.74M——
Total debt$24.74M——
Total liabilities$61.55M$38.06M$26.02M
Shareholders' equity$232.28M$266.59M-$13.14M
Net debt-$99.35M——
Shares outstanding60.39M43.21M1.25M
Cash flow statement
Operating cash flow-$153.71M-$114.25M-$52.41M
Capital expenditure$5,000$2.21M$621,000
Free cash flow-$153.72M-$116.45M-$53.03M
Investing cash flow$40.02M-$160.90M-$8.79M
Financing cash flow$141.17M$337.11M$58.12M
Depreciation & amortization$1.80M$2.13M$1.71M
Stock-based compensation$10.08M$8.36M$2.22M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.